Figure 4 | Scientific Reports

Figure 4

From: A screen of FDA-approved drugs identifies inhibitors of protein tyrosine phosphatase 4A3 (PTP4A3 or PRL-3)

Figure 4

Salirasib and Candesartan inhibit PRL-3 induced cell migration in HEK293T cells. (a) Quantification of cell migration of HEK293T cells transfected with a either PRL-3 expression vector or empty vector control. Cells from (a) were treated with either (b) Salirasib or (c) Candesartan at the doses indicated. The zero drug dose was a 1% DMSO control, and each data set was compared to the DMSO control group within that data set. Both drugs inhibited cell migration to a greater extent in the PRL-3 overexpressing cells, compared to empty vector (EV) control. *p = 0.089 using one tailed student t test with Holm Sidak correction, **p = 0.03, ***p = 0.001, ns = no significant difference, using a two-way ANOVA with Dunnett’s correction.

Back to article page